Successful transjugular intrahepatic portal-systemic shunt in an ineligible liver transplant patient with primary biliary cirrhosis with refractory ascites and aplastic anemia


A transjugular intrahepatic portal-systemic shunt (TIPS) is a standard way to decompress the portal system in cirrhotic patients as a bridge to orthotopic liver transplantation (OLT). Traditionally, TIPS has been indicated for certain portal hypertensive sequelae such as refractory ascites, varices treatment and even hepato-hydrothorax. Herein is a case report on the efficacy of TIPS in an OLT ineligible patient with primary biliary cirrhosis and aplastic anemia who had developed refractive ascites requiring serial paracentesis and esophageal varices. He survived 2.5 years post-TIPS placement and died from complications related to severe leucopenia and the development of sepsis.

Share and Cite:

Moore, C. , Behrens, G. , Ferral, H. and Thiel, D. (2013) Successful transjugular intrahepatic portal-systemic shunt in an ineligible liver transplant patient with primary biliary cirrhosis with refractory ascites and aplastic anemia. Open Journal of Gastroenterology, 3, 1-4. doi: 10.4236/ojgas.2013.31001.

Conflicts of Interest

The authors declare no conflicts of interest.


[1] Rössle, M., Ochs, A., Gulberg, V., Siegerstetter, V., Holl, J., Deibert, P., et al. (2000) A comparison of paracentesis and transjugular intrahepatic portosystemic shunting in patients with ascites. New England Journal of Medicine, 342, 1701-1707. doi:10.1056/NEJM200006083422303?
[2] Saab, S., Nieto, J.M., Lewis, S.K. and Runyon, B.A. (2006) TIPS versus paracentesis for cirrhotic patients with refractory ascites. Cochrane Database of Systematic Reviews, 18, Article ID: CD004889.
[3] Boyer, T.D. and Haskal, Z.J. (2010) American association for the study of liver diseases. The role of transjugular intrahepatic portosystemic shunt (TIPS) in the management of portal hypertension: Update 2009. Hepatology, 51, 306. doi:10.1002/hep.23383
[4] Lefton, H.B., Rosa, A. and Cohen, M. (2009) Diagnosis and epidemiology of cirrhosis. Medical Clinics of North America, 93, 787-799. doi:10.1016/j.mcna.2009.03.002
[5] Runyon, B.A. (2009) AASLD practice guidelines committee. Management of adult patients with ascites due to cirrhosis: An update. Hepatology, 49, 2087-2107. doi:10.1002/hep.22853
[6] Campbell, M.S., Brensinger, C.M., Sanyal, A.J., et al., Quality of life in refractory ascites: Transjugular intrahepatic portal-systemic shunting versus medical therapy. Hepatology, 42, 635-640. doi:10.1002/hep.20840
[7] Fidelman, N., Kwan, S.W., Laberge, J.M., Gordon, R.L., Ring, E.J. and Kerlan Jr., R.K. (2012) The transjugular intrahepatic portosystemic shunt: An update. American Journal of Roentgenology, 199, 746-755. doi:10.2214/AJR.12.9101
[8] Young, N.S., Bacigalupo, A. and Marsh, J.C. (2010) Aplastic anemia: Pathophysiology and treatment. Biology of Blood and Marrow Transplantation, 16, S119-S125. doi:10.1016/j.bbmt.2009.09.013
[9] Runyon, B.A., Antillon, M.R. and McHutchison, J.G. (1992) Diuresis increases ascitic fluid opsonic activity in patients who survive spontaneous bacterial peritonitis. Journal of Hepatology, 14, 249-252. doi:10.1016/0168-8278(92)90166-M
[10] Plauth, M., Schutz, T., Buckendahl, D.P., et al. (2004) Weight gain after transjugular intrahepatic portosystemic shunt is associated with improvement in body composition in malnourished patients with cirrhosis and hypermetabolism. Journal of Hepatology, 40, 228-233. doi:10.1016/j.jhep.2003.10.011

Copyright © 2024 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.